GIPR - gastric inhibitory polypeptide receptor Gene

Also Known as PGQTL2

Species: Homo sapiens

Gene Type: protein coding

Gene ID: 2696

About GIPR

Cytogenetic location: 19q13.32 Genomic coordinates (GRCh38): 19:45,668,221-45,683,722 (from NCBI)

This gene has 9 transcripts (splice variants), 93 orthologues and 42 paralogues. Broad expression in stomach (RPKM 5.3), fat (RPKM 1.5) and 16 other tissues.

Summary

This gene encodes a G-protein coupled receptor for gastric inhibitory polypeptide (GIP), which was originally identified as an activity in gut extracts that inhibited gastric acid secretion and Gastrin release, but subsequently was demonstrated to stimulate Insulin release in the presence of elevated glucose. Mice lacking this gene exhibit higher blood glucose levels with impaired initial Insulin response after oral glucose load. Defect in this gene thus may contribute to the pathogenesis of diabetes. [provided by RefSeq, Oct 2011]

GIPR Products (2)

mRNA	Protein	Name
NM_000164.4	NP_000155.1	gastric inhibitory polypeptide receptor isoform 1 precursor
NM_001308418.2	NP_001295347.1	gastric inhibitory polypeptide receptor isoform 2 precursor

Gene Ontology

Molecular Function
Biological Process

Molecular Function GO Annotation	Evidence	References	Source
enables gastric inhibitory peptide receptor activity	IDA IDA: Inferred from direct assay	26572091	GOA
enables glucagon family peptide binding	IPI IPI: Inferred from physical interaction	17715056	GOA
enables peptide hormone binding	IPI IPI: Inferred from physical interaction	17715056	GOA
enables protein binding	IPI IPI: Inferred from physical interaction	17715056	GOA

Biological Process GO Annotation	Evidence	References	Source
involved in adenylate cyclase-activating G protein-coupled receptor signaling pathway	IDA IDA: Inferred from direct assay	26572091	GOA
involved in gastric inhibitory peptide signaling pathway	IDA IDA: Inferred from direct assay	26572091	GOA

EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern

GIPR Protein Structure

HRM

7tm_2

0
100
200
300
400
466 a.a.

Protein Preferred Names	Protein Names
gastric inhibitory polypeptide receptor	GIP-R

GIPR Protein-protein interaction Information

Type	Protein Name	Protein ID	Interactor	Interactor Species	Interactor ID	Detection Method	References
Intra	GIPR	P48546	GCG	Homo sapiens	P01275	ITC	17715056
Intra	GIPR	P48546	GCG	Homo sapiens	P01275	CD	17715056
Intra	GIPR	P48546	GIP	Homo sapiens	P09681	X-Ray Diffraction	17715056
Intra	GIPR	P48546	GIP	Homo sapiens	P09681	CD	17715056
Intra	GIPR	P48546	GIP	Homo sapiens	P09681	ITC	17715056

Cross: Cross-species interaction Intra: Intraspecies interaction

Related Diseases

Diseases	Alias
Adrenal Cortical Adenoma	Adrenocortical Adenoma Adenoma Adrenocortical
Adrenal Adenoma	Adenoma Of The Adrenal Gland Adrenal Incidentaloma Adrenal Cortical Adenoma Adrenocortical Adenoma
Conn'S Syndrome	Cushing Syndrome Hyperaldosteronism Primary Hyperaldosteronism Hypercortisolism Primary Aldosteronism Cushing'S Syndrome Adrenal Gland Hyperfunction Conn Syndrome Hyperadrenalism Ectopic Acth Syndrome Hyperadrenocorticism Cushing Disease Cushing'S Disease Adrenal Cortex Adenoma Corticotroph Pituitary Adenoma Pituitary Corticotroph Micro-Adenoma Pituitary-Dependent Cushing Syndrome Pituitary Acth Hypersecretion Acth Syndrome, Ectopic Acth-Secreting Pituitary Adenoma Adrenal Hyperfunction Resulting From Pituitary Acth Excess Ectopic Adrenocorticotropic Hormone Syndrome Nodular Primary Adrenocortical Dysplasia Pituitary Dependent Cushing Syndrome Pituitary Cushing Syndrome Pituitary-Dependant Cushing Syndrome Pituitary-Dependant Hypercortisolism Pituitary-Dependant Hypercortisolism Disorder Aldosteronism Primary Acth Syndrome Ectopic Adrenal Cushing'S Syndrome Adrenal Cortical Adenoma Cushing Syndrome Nos Cortisol Hypersecretion Corticoadrenal Hypersecretion Cushing Syndrome Secondary To Ectopic Acth-Secretion Ectopic Cushing Syndrome Hypercortisolism Due To Nonpituitary Tumour Ectopic Acth - [Adrenocorticotropic Hormone] Secretion Ectopic Acth - [Adrenocorticotropic Hormone] Secretion Causing Cushing Syndrome Idiopathic Aldosteronism Aldosteronism Primary Aldosteronism Due To Bilateral Adrenal Hyperplasia Primary Aldosteronism Due To Adrenal Hyperplasia
Insulinoma	Islet Cell Adenoma Insulin-Producing Tumor Of Islet Cells Adenoma Islet Cell Islet Cell Tumor Experimental Organism Islet Cell Adenoma Neoplasm
Acth-Independent Macronodular Adrenal Hyperplasia	Acth-Independent Macronodular Adrenocortical Hyperplasia Adrenocorticotropic Hormone-Independent Macronodular Adrenal Hyperplasia Corticotropin-Independent Macronodular Adrenal Hyperplasia Cushing Syndrome Due To Macronodular Adrenal Hyperplasia AIMAH1 Aimah Massive Macronodular Adrenocortical Disease Mmad Primary Macronodular Adrenal Hyperplasia Cushing Syndrome, Adrenal, Due To Aimah Primary Bilateral Macronodular Adrenal Hyperplasia Acth-Independent Macronodular Adrenal Hyperplasia 1 Acth-Independent Cushing Syndrome Adrenal Cushing Syndrome Due To Aimah Acth-Independent Macronodular Adrenal Hyperplasia 2
Breast Ductal Adenoma
Isolated Growth Hormone Deficiency, Type Ib	Isolated Growth Hormone Deficiency Type Ib IGHD1B Ighd Ib Growth Hormone Deficiency, Isolated, Type Ib Congenital Ighd Type Ib Congenital Isolated Gh Deficiency Type Ib Congenital Isolated Growth Hormone Deficiency Type Ib Dwarfism Of Sindh Pituitary Dwarfism I Isolated Growth Hormone Deficiency Type 1b Ighd 1b Growth Hormone Deficiency, Isolated, 1b
Type 2 Diabetes Mellitus	Insulin Resistance NIDDM Type 2 Diabetes Diabetes Mellitus, Non-Insulin-Dependent T2D Noninsulin-Dependent Diabetes Mellitus Diabetes Mellitus, Type Ii Maturity-Onset Diabetes Insulin Resistance, Severe, Digenic Diabetes Mellitus, Type 2 Diabetes Mellitus, Noninsulin-Dependent Diabetes Mellitus, Noninsulin-Dependent, Association With Diabetes Mellitus, Noninsulin-Dependent, Late Onset Hypertension, Insulin Resistance-Related, Susceptibility To Insulin Resistance, Susceptibility To Non-Insulin-Dependent Diabetes Mellitus Type Ii Diabetes Mellitus Adult-Onset Diabetes Mellitus Maturity-Onset Diabetes Mellitus Diabetes Mellitus Type 2 Type Ii Diabetes Type 2 Diabetes Mellitus, Susceptibility To Diabetes, Type 2 Diabetes Mellitus, Noninsulin-Dependent, Susceptibility To Diabetes Mellitus, Non-Insulin-Dependent, Susceptibility To Diabetes Mellitus, Type 2, Susceptibility To Diabetes Mellitus, Noninsulin-Dependent, 2 Diabetes Mellitus, Type Ii, Susceptibility To Hypertension, Insulin Resistance-Related Adult-Onset Diabetes Aodm Diabetes Mellitus, Adult-Onset Diabetes Mellitus Type Ii Diabetes Mellitus Type 2, Susceptibility To Diabetes, Type Ii, Susceptibility To Diabetes Type 2 Diabetes Mellitus Adult Onset Diabetes Maturity Onset Diabetes Nonketotic Diabetes Non-Insulin Dependent Diabetes Mellitus T2dm - [Type 2 Diabetes Mellitus] Niddm - [Non Insulin Dependent Diabetes Mellitus] Dm2 Dm Type Ii Diabetic Type 2 Insulin Requiring Type 2 Diabetes Noninsulin Dependent Diabetes Non-Insulin-Dependent Diabetes Mellitus Without Complications Diabetes Due To Insulin Secretory Defect Diabetes Mellitus Due To Insulin Secretory Defect Non-Insulin-Dependent Diabetes Of The Young Senile Diabetes Nonketotic Hyperglycaemia Stable Diabetes
Diabetes Mellitus	Diabetes

Diseases	Alias
Waldenstroem'S Macroglobulinemia	Waldenstroem'S Macroglobulinemia Waldenstroem'S Macroglobulinemia Macroglobulinemia Of Waldenstrom Lymphoplasmacytic Lymphoma With Igm Gammopathy Lymphoplasmacytic Lymphoma Waldenstroem'S Macroglobulinemia Waldenstroem'S Macroglobulinemia Macroglobulinemia Of Waldenstrom Lymphoplasmacytic Lymphoma With Igm Gammopathy Lymphoplasmacytic Lymphoma

Related Agents

Clinical Phase
Pre-clinical Phase

Clinical Phase

Bioactive Molecules (3)

Cat. No.	Product Name	Effect	Purity	Phase
HY-P11672	Poterepatide	Agonist	99.78%	Phase 3
HY-P3506B	Retatrutide acetate	Agonist	99.69%	Phase 3
HY-164535	Maridebart cafraglutide		99.24%	Phase 1

Bioactive MoleculesInhibitory Antibodies (1)

Cat. No.	Product Name	Effect	Purity	Phase
HY-P990047	Maridebart	Inhibitor	99.90%	Phase 3

Pre-clinical Phase

Bioactive Molecules (28)

Cat. No.	Product Name	Effect	Purity	Rare Diseases
HY-P3506	Retatrutide	Agonist	99.96%	Unkown
HY-P10735	GIP (mouse)		98.79%	Unkown
HY-P3506A	Retatrutide TFA	Agonist	99.47%	Unkown
HY-P10736A	AMG133 peptide payload TFA	Agonist	99.70%	Unkown
HY-P10736	AMG133 peptide payload		99.94%	Unkown
HY-P10302A	GLP-1R/GIPR agonist-1 (soduim)	Agonist	98.24%	Unkown
HY-P10271	RG7697	Agonist	99.90%	Unkown
HY-P11321A	IUB0271 hydrochloride		98.67%	Unkown
HY-P3584A	(Pro3) GIP, human TFA		99.89%	Unkown
HY-P10031	SAR441255	Agonist	99.84%	Unkown
HY-P10031A	SAR441255 TFA	Agonist	99.93%	Unkown
HY-186050	GIPR antagonist 2	Agonist	99.48%	Unkown
HY-P10302	GLP-1R/GIPR agonist-1	Agonist	/	Unkown
HY-P3584	(Pro3) GIP, human	Agonist	99.79%	Unkown
HY-171302	GLP-1R/GIPR agonist-2	Agonist	/	Unkown
HY-173479	GLP-1R agonist 30	Agonist	/	Unkown
HY-179332	GIPR antagonist 1		/	Unkown
HY-181709	TPM003	Agonist	/	Unkown
HY-182580	HBK001		/	Unkown
HY-P11275	TC4	Agonist	/	Unkown
HY-P11279	TC2	Agonist	/	Unkown
HY-P11321	IUB0271		/	Unkown
HY-P11487	UTG-4	Agonist	/	Unkown
HY-P11818	GIPR/GLP-1R/GCGR agonist-1		/	Unkown
HY-P11880	LY3324954	Agonist	/	Unkown
HY-RS05437	GIPR Human Pre-designed siRNA Set A	Pre-designed Set	/	Unkown
HY-RS17884	Gipr Mouse Pre-designed siRNA Set A	Pre-designed Set	/	Unkown
HY-RS24353	Gipr Rat Pre-designed siRNA Set A	Pre-designed Set	/	Unkown

Orthologs Information

Species	Symbol	Source	ID
Canis familiaris	GIPR	VGNC	VGNC:41228
Mus musculus	GIPR	MGD	MGI:1352753
Bos taurus	GIPR	VGNC	VGNC:29367
Rattus norvegicus	GIPR	RGD	RGD:2689
Macaca mulatta	GIPR	VGNC	VGNC:73052
Felis catus	GIPR	VGNC	VGNC:62559
Others	GIPR	NCBI